Work

Phase II study of pembrolizumab with enzalutamide (Enz) in metastatic, castration-resistant prostate cancer (mCRPC): 30 patient expansion with examination of tumour-infiltrating immune cells and fecal microbiota

Year: 2019

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz248.005

Authors: J.N. Graff, A.E. Moran, R.E. Slottke, G.V. Thomas, J.J. Alumkal, R.F. Thompson, M.A. Wood, L.B. Peiffer, R.C. Bergan, K.S. Sfanos, T.M. Beer

Institutions: Oregon Health & Science University, OHSU Knight Cancer Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Endocyte, Clovis Oncology, Eisai, Astellas Pharma, Ipsen, Aptitude Health, Genentech, Chugai Pharmaceutical, Janssen Biotech

OpenAlex ID: W2977866745

FWCI: 0.826

Cites:

Cited by: 5

Related to: 10